Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial. Issue 6 (December 2016)

• Record Type: Journal Article
• Authors: Stallings, Virginia A.; Schall, Joan I.; Maqbool, Asim; Mascarenhas, Maria R.; Alshaikh, Belal N.; Dougherty, Kelly A.; Hommel, Kevin; Ryan, Jamie; Elci, Okan U.; Shaw, Walter A.
• Is Part Of: Journal of pediatric gastroenterology and nutrition. Volume 63:Issue 6(2016)
• Page Start: 676
• Page End: 680
• Publication Date: 2016-12
• Subjects: fatty acids -- linoleic acid -- LYM-X-SORB -- pancreatic insufficiency; Children -- Nutrition -- Periodicals; Pediatric gastroenterology -- Periodicals; Infants -- Nutrition -- Periodicals; Nutrition disorders in children -- Periodicals; Child Nutrition -- Periodicals; Digestive System -- growth & development -- Periodicals; Gastrointestinal Diseases -- Periodicals; Infant Nutrition -- Periodicals; Nutrition Disorders -- Periodicals; Child; 618.923
• DOI: 10.1097/MPG.0000000000001213
• Languages: English
• ISSNs: 0277-2116

Abstract

Abstract : Supplemental Digital Content is available in the text Abstract : ABSTRACT: Pancreatic enzyme therapy does not normalize dietary fat absorption in patients with cystic fibrosis and pancreatic insufficiency. Efficacy of LYM-X-SORB (LXS), an easily absorbable lipid matrix that enhances fat absorption, was evaluated in a 12-month randomized, double-blinded, placebo-controlled trial with plasma fatty acids (FA) and coefficient of fat absorption (CFA) outcomes. A total of 110 subjects (age 10.4 ± 3.0 years) were randomized. Total FA increased with LXS at 3 and 12 months (+1.58, +1.14 mmol/L) and not with placebo ( P = 0.046). With LXS, linoleic acid (LA) increased at 3 and 12 months (+298, +175 nmol/mL, P ≤ 0.046), with a 6% increase in CFA ( P < 0.01). LA increase was significant in LXS versus placebo (445 vs 42 nmol/mL, P = 0.038). Increased FA and LA predicted increased body mass index Z scores. In summary, the LXS treatment improved dietary fat absorption compared with placebo as indicated by plasma FA and LA and was associated with better growth status.